Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review

Table 2

Rivaroxaban dosage in various indications.

Indication	GFR	Dose
Nonvalvular AFib	>50 mL/min	20 mg daily
	15-50 mL/min	15 mg daily
	<15 mL/min	Not recommended
Treatment of DVT/PE	>30 mL/min	15 mg BID for 3 weeks followed by 20 mg daily.
	<30 mL/min	Not recommended
DVT/PE prophylaxis in hip and knee surgery	>30 mL/min	10 mg daily
	<30 mL/min	Not recommended
DVT/PE prophylaxis in acute medical illness	>30 mL/min	10 mg daily
	<30 mL/min	Not recommended
Stable coronary artery disease	>30 mL/min	2.5 mg BID
	15-30 mL/min	2.5 mg BID with caution
	<15 mL/min	Not recommended
Peripheral artery disease	>30 mL/min	2.5 mg BID
	15-30 mL/min	2.5 mg BID with caution
	<15 mL/min	Not recommended
Acute coronary artery syndrome	>30 mL/min	2.5 BID
	15-30 mL/min	2.5 mg BID with caution
	<15 mL/min	Not recommended

GFR: glomerular filtration rate; BID: twice daily; AFib: atrial fibrillation; DVT/PE: deep vein thrombosis/pulmonary embolism.